Denosumab Attenuates Knee Osteoarthritis Progression by Inhibiting Synovial Inflammation Via the RANK/TRAF6/FSTL1 Signalling Pathway

Wei Tong,Yuxiang Hu,Wei Chen,Shenghui Lan,Chaochang Ming,Dongdong Xu,Haitao Li,Hao Xu,Deyao Shi,Weijian Liu,Zhipeng Dai,Jian Wang,Zhili He,Weihua Xu,Zengwu Shao,Yong Liu,Hongtao Tian

DOI: https://doi.org/10.21203/rs.3.rs-4861749/v1

2024-01-01

Abstract:Synovitis plays a critical role in osteoarthritis (OA), and inhibiting synovitis can significantly alleviate OA symptoms. Denosumab, a monoclonal antibody targeting RANKL, inhibits the RANK/NF-κB pathway in monocyte–macrophage lineage cells, crucial in inflammation. Here, we report a novel role of denosumab in fibroblast-like synoviocytes (FLSs) where it attenuates synovitis and OA progression. We first demonstrated that RANKL and RANK were highly expressed in synovium of OA mice and patients. Denosumab, administered systemically via injection, was primarily enriched in the synovium and effectively reduced synovitis, thereby delaying OA progression in post-traumatic, inflammatory, and aged OA mouse models. Mechanistically, single-cell RNA sequencing (scRNA-seq) showed that FLSs were the most significantly altered cell cluster in joint cells, and cell–cell interaction analysis indicated enhanced FLS–chondrocyte crosstalk in OA, which was markedly reduced following denosumab treatment, suggesting FLSs as the primary responsive cells to denosumab in OA joints. Furthermore, immunoprecipitation assay revealed that RANKL promoted RANK–TRAF6 binding, activating the NF-κB signalling pathway, leading to the upregulation of various pro-inflammatory and chondrocyte catabolic cytokines in FLSs. Further sequencing analysis and western blotting identified follistatin-like protein 1 (FSTL1) as the most upregulated cytokine in FLSs, inducing inflammatory reactions and chondrocyte catabolism, effects that were significantly inhibited by denosumab. Consistent with the mouse model, we observed reduced synovitis and OA progression in a beagle dog model of OA. Finally, a single-arm clinical trial demonstrated that denosumab alleviated synovitis and pain, improved joint function in knee OA patients, associated with reduced expression of pro-inflammatory and chondrocyte catabolic cytokines in FLSs induced by FSTL1. These findings provide a translational basis for using denosumab to treat knee OA patients.